An update on osteoarthritis therapeutics.
OBJECTIVE
This review addresses recent major developments in symptomatic therapy and the principles of disease modification in osteoarthritis. It emphasizes issues that are of importance to the practicing clinician at a time when researchers in the field are trying to improve ways not only to provide symptomatic relief but also to slow disease progression.


RESULTS
The past year has led to a reassessment of the role of cyclo-oxygenase-2 inhibitors in osteoarthritis therapy and has yielded new information on nutriceuticals such as glucosamine. The relative efficacy of intra-articular injections of agents such as corticosteroid and hyaluronic acid preparations has been assessed. In addition, reports on trials of potentially disease-modifying agents for osteoarthritis have been published.


CONCLUSIONS
Because the therapeutic options have been reduced over the past year and the role of nutritional supplements remains unclear, the clinician is faced with a need to reassess osteoarthritis therapy. Although no practical disease-modifying agent for osteoarthritis has been identified, reports such as the recent doxycycline trial reviewed herein provide hope that continued research will soon yield a therapeutic model similar to that used in rheumatoid arthritis, for which some therapeutic agents achieve disease modification and other agents can be added as needed for symptomatic relief.
Hogenmiller
M Scott
MS
Department of Medicine, Jackson Memorial Hospital, Miami, Florida, USA.
Lozada
Carlos J
CJ
D052246:Cyclooxygenase 2 Inhibitors / Q000627:therapeutic use; D006801:Humans; D010003:Osteoarthritis / Q000188:drug therapy* / Q000503:physiopathology
D052246:Cyclooxygenase 2 Inhibitors